Concurrent Bupropion / Varenicline for Smoking Cessation
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This study focuses on the first step in developing an algorithm for maximizing quit-smoking
success based on an adaptive approach, which changes treatment from the initial nicotine
replacement therapy (NRT) when that treatment alone may not be sufficient. These NRT
"non-responders" are switched (in double-blind fashion) before the quit date to receive
either varenicline alone or varenicline paired with bupropion. Some participants who would
otherwise have failed at their quit smoking attempt could be "rescued" by switching to
alternative pharmacotherapies. The proposed study will evaluate the combination treatment
against varenicline alone in an adaptive trial design
Phase:
Phase 3
Details
Lead Sponsor:
Duke University
Collaborators:
National Institute on Drug Abuse (NIDA) Philip Morris USA, Inc.